EZH2 and breast carcinoma: Subsequent studies by Alison Hirukawa have further proven that EZH2 sustains the suppression of the FOXC1 gene through H3K27me3, thereby deactivating an anti-invasive transcriptional program driven by FOXC1 in Luminal B breast cancer [130].